Longitudinal interferon-β effects in multiple sclerosis: differential regulation of IL-10 and IL-17A, while no sustained effects on IFN-γ, IL-4 or IL-13
2013 (English)In: Journal of the Neurological Sciences, ISSN 0022-510X, E-ISSN 1878-5883, Vol. 325, no 1-2, 79-85 p.Article in journal (Refereed) Published
Recent studies in experimental models and in vitro indicate lowering of IL-17/Th17 as an important mechanism of interferon-beta (IFN-β) treatment in multiple sclerosis (MS).
Material and methods:
In this longitudinal study of MS patients (n = 25), spontaneous and myelin antigen-induced secretion of IL-4, IFN-γ and IL-10 (ELISPOT), mitogen stimulated secretion of IL-13 and IL-17A (ELISA) and circulating cytokine levels (Luminex) were recorded at inclusion and after 1.5, 3, 6 and 12 months of IFN-β treatment.
Early changes were noted for IL-4, while after one year of treatment the only recorded significant effects were a decrease in secreted IL-17A levels and an increase in IL-10 secreting cells. While IL-17A levels tended to be higher in non-responders (n = 8), the decrease in IL-17A levels seemed to be more pronounced in responders (n = 17) showing significantly lower IL-17A levels after one year as compared with non-responders.
IFN-β treatment seems to mainly affect IL-17/IL-10-associated pathways rather than the IFN-γ/IL-4 axis.
Place, publisher, year, edition, pages
Elsevier , 2013. Vol. 325, no 1-2, 79-85 p.
Multiple sclerosis, Interferon-beta, Cytokines, IL-4, IL-17, IL-10, Responder
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-90199DOI: 10.1016/j.jns.2012.12.001ISI: 000315323000016OAI: oai:DiVA.org:liu-90199DiVA: diva2:612363
Funding Agencies|Biogen Idec||Network for Inflammation research||Swedish Foundation for Strategic Research||Swedish Association of Neurologically Disabled||County Council of Ostergotland||University Hospital of Linkoping and Lions Ostergotland||2013-04-032013-03-212013-08-29Bibliographically approved